Table 4.
Multivariate analysis of the association between patient/transplant characteristics and HSCT outcomes
| OS |
PFS |
TRM |
Relapse |
aGVHD 2-4 |
aGVHD 3-4 |
cGVHD |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% ci) | P value | HR (95% ci) | P value | HR (95% ci) | P value | HR (95% ci) | P value | HR (95% ci) | P value | HR (95% ci) | P value | HR (95% ci) | P value | |
| Clinically relevant HHV-6 infection | 1.13 (0.69-1.84) | .63 | 0.94 (0.58-1.54) | .82 | 1.08 (0.52-2.25) | .84 | 0.88 (0.45-1.71) | .70 | 3.32 (1.65-6.69) | <.01 | 4.13 (1.58-10.79) | <.01 | 0.84 (0.42-1.69) | .62 |
| Age > 53 y | 1.17 (0.77-1.78) | .47 | 1.19 (0.79-1.79) | .41 | 1.81 (0.96-3.41) | .07 | 0.82 (0.47-1.45) | .49 | 0.76 (0.44-1.30) | .31 | 0.81 (0.39-1.67) | .56 | 1.08 (0.62-1.89) | .80 |
| Disease (vs AML) | .45 | .13 | .62 | .05 | .14 | .92 | <.01 | |||||||
| Lymphoma/MM | 1.05 (0.61-1.81) | .86 | 1.20 (0.72-2.01) | .49 | 1.40 (0.64-3.09) | .40 | 0.97 (0.48-1.97) | .94 | 0.76 (0.35-1.65) | .48 | 1.00 (0.38-2.67) | .99 | 2.66 (1.24-5.71) | .01 |
| MDS/MPN | 0.68 (0.35-1.33) | .26 | 0.59 (0.30-1.14) | .11 | 1.42 (0.58-3.49) | .44 | 0.25 (0.08-0.77) | .02 | 1.92 (0.87-4.22) | .11 | 1.27 (0.39-4.15) | .70 | 3.08 (1.32-7.22) | <.01 |
| Disease status (vs CR1) | <.01 | <.01 | .25 | <.01 | .49 | .26 | .19 | |||||||
| Active disease | 1.06 (0.46-2.45) | .90 | 1.12 (0.49-2.52) | .79 | 1.50 (0.53-4.26) | .45 | 0.70 (0.17-2.83) | .62 | 1.44 (0.53-3.90) | .48 | 1.31 (0.33-5.18) | .70 | 0.79 (0.32-1.99) | .62 |
| CR>1 | 2.95 (1.66-5.25) | <.01 | 3.28 (1.84-5.82) | <.01 | 1.99 (0.88-4.46) | .10 | 4.77 (2.09-10.86) | <.01 | 1.52 (0.76-3.02) | .24 | 2.18 (0.82-5.83) | .12 | 1.56 (0.76-3.18) | .22 |
| HCT-CI>2 | 1.57 (1.03-2.40) | .04 | 1.30 (0.86-1.94) | .21 | 1.18 (0.64-2.17) | .60 | 1.29 (0.74-2.26) | .36 | 0.94 (0.54-1.62) | .82 | 0.89 (0.42-1.90) | .77 | 1.19 (0.66-2.12) | .57 |
| Previous allo-HSCT | 0.59 (0.26-1.34) | .20 | 0.54 (0.24-1.23) | .14 | 0.35 (0.08-1.55) | .17 | 0.72 (0.27-1.94) | .52 | 1.05 (0.40-2.71) | .93 | 1.24 (0.37-4.11) | .73 | 1.46 (0.58-3.69) | .43 |
| MAC (vs RTC) | 1.01 (0.47-2.13) | .99 | 0.97 (0.45-2.06) | .93 | 0.94 (0.34-2.55) | .90 | 1.20 (0.36-3.97) | .76 | 0.67 (0.29-1.55) | .35 | 0.52 (0.16-1.67) | .27 | 1.08 (0.40-2.96) | .88 |
| Donor (vs haplo) | .29 | .65 | 1.00 | .82 | .31 | .67 | .01 | |||||||
| MRD | 0.57 (0.26-1.23) | .15 | 0.73 (0.35-1.52) | .40 | 0.00 (0.00-5.81) | .97 | 1.30 (0.58-2.89) | .53 | 0.44 (0.15-1.30) | .14 | 0 (0-1.61) | .97 | 0.32 (0.09-1.18) | .09 |
| MUD | 1.12 (0.53-2.34). | .77 | 1.08 (0.53-2.19) | .84 | 1.04 (0.38-2.83) | .95 | 1.06 (0.37-3.02) | .91 | 0.73 (0.29-1.84) | .50 | 0.56 (0.16-1.98) | .37 | 0.29 (0.12-1.69) | <.01 |
| PBSC (vs BM) | 2.72 (1.07-6.91) | .04 | 2.54 (1.08-5.99) | .03 | 1.30 (0.43-3.89) | .64 | 4.53 (1.07-19.23) | .04 | 1.26 (0.47-3.35) | .65 | 2.98 (0.39-22.75) | .29 | 2.52 (0.71-8.91) | .15 |
| PT-Cy (vs ATG) | 0.74 (0.39-1.41) | .36 | 0.69 (0.37-1.30) | .25 | 1.22 (0.50-2.98) | .67 | 1.58 (0.64-3.93) | .32 | 0.95 (0.43-2.11) | .90 | 0.60 (0.21-1.74) | .35 | 0.81 (0.39-1.67) | .57 |
| CMV status neg/neg (vs others) | 0.76 (0.36-1.60) | .47 | 0.80 (0.39-1.64) | .54 | 0.63 (0.21-1.89) | .41 | 0.95 (0.36-2.53) | .92 | 0.87 (0.32-2.37) | .79 | 0.57 (0.12-2.63) | .47 | 1.36 (0.60-3.12) | .46 |
Risk factors with a significant influence on outcomes and their respective HRs are shown in bold.
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; ATG, antithymocyte globulin; AML, acute myeloid leukemia; BM, bone marrow; CR, complete remission; haplo, haploidentical; HCT-CI, hematopoietic cell transplant–comorbidity index; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, myeloproliferative neoplasms; MRD, matched-related donor; MUD, matched-unrelated donor; neg, negative; PBSC, peripheral blood stem cells; RTC, reduced-toxicity conditioning.